DNMT1 and carcinoma: Different classes of ITCs have been reported to exert their anti-cancer activity through the modulation of distinct epigenetic processes (including alterations in DNMT expression patterns) in various cancer models like prostate [56,57,58] and breast [59] carcinomas.